Although the histopathological findings in our study did not show significant alterations in hepatic inflammation and fibrosis, diminished levels of Col1a1 and Saa1 mRNAs suggest a potential role of genistein treatment in slowing MASLD progression. Here, SAA1 is linked to metabolic dysfunction-associated steatotic liver disease.